<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671460</url>
  </required_header>
  <id_info>
    <org_study_id>TianjinMycure-LDP-CD19 CAR-T</org_study_id>
    <nct_id>NCT03671460</nct_id>
  </id_info>
  <brief_title>CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.</brief_title>
  <official_title>Phase I Study of the Safety and Efficacy of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Mycure Medical Technology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Mycure Medical Technology Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-lable phase 1 study to determine the safety and
      efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell
      lymphoblastic leukemia (R/R B-ALL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single-center, open-label, nonrandomized, no control, prospective clinical trial, no
      less than 18 CD19+ B-cell relapsed or refractory acute B-cell lymphoblastic leukemia (R/R
      B-ALL) patients will be enrolled. Side effects of CD19 CAR T cells therapy will be monitored.
      The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T
      cells therapy in patients with R/R B-ALL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 7, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single-center, open-label, nonrandomized, no control, prospective clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of participants with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of participants who achieved complete remission (CR) over all participants (CRR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective remission rate</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of participants who achieved complete remission (CR) and partial remission over all participants (ORR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CD19-CAR-T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 CAR-T cells</intervention_name>
    <description>T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.</description>
    <arm_group_label>CD19-CAR-T Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than 1 year;

          2. CD19 positive B-cell acute lymphoblastic leukemia;

          3. Important organ function is satisfied: cardiac ultrasound indicates cardiac ejection
             fraction ≥50%, no obvious abnormality in ECG; blood oxygen saturation ≥90%; creatinine
             clearance calculated by Cockcroft-Gault formula ≥40ml/min; ALT and AST≤ 5 times normal
             range, total bilirubin ≤ 34.2 μmol / L.

          4. Expected to survive for more than 3 months;

          5. Informed consent is signed by a subject or his lineal relation.

        Exclusion Criteria:

          1. Recent or current use of glucocorticoid or other immunosuppressor;

          2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;

          3. Has a graft-versus-host response and requires the use of immunosuppressants；

          4. Drug uncontrollable central nervous system leukemia；

          5. Pregnant or lactating female；

          6. The patient did not agree to use effective contraception during the treatment period
             and for the following 1 year；

          7. A history of other malignant tumors;

          8. The investigator believes that there are other factors that are not suitable for
             inclusion or influence the subject's participation or completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peihua Lu, PhD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chaoting Zhang, PhD</last_name>
    <phone>86-010-88196768</phone>
    <email>zhangchaoting1@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <zip>065000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, MD, PhD</last_name>
      <phone>18611636172</phone>
      <email>peihua_lu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell acute lymphoblastic leukemia</keyword>
  <keyword>CD19 CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We don't decide when to share IPD and what will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

